Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Patients with type 1 diabetes who do aerobic exercise often experience a drop in blood glucose concentration that can result in hypoglycemia. Current approaches to prevent exercise-induced hypoglycemia include reduction in insulin dose or ingestion of carbohydrates, but these strategies may still result in hypoglycemia or hyperglycemia. We sought to determine whether mini-dose glucagon (MDG) given subcutaneously before exercise could prevent subsequent glucose lowering and to compare the glycemic response to current approaches for mitigating exercise-associated hypoglycemia. RESEARCH DESIGN AND METHODS: We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO2max for 45 min under conditions of no intervention (control), 50% basal insulin reduction, 40-g oral glucose tablets, or 150-μg subcutaneous glucagon (MDG). RESULTS: During exercise and early recovery from exercise, plasma glucose increased slightly with MDG compared with a decrease with control and insulin reduction and a greater increase with glucose tablets (P < 0.001). Insulin levels were not different among sessions, whereas glucagon increased with MDG administration (P < 0.001). Hypoglycemia (plasma glucose <70 mg/dL) was experienced by six subjects during control, five subjects during insulin reduction, and none with glucose tablets or MDG; five subjects experienced hyperglycemia (plasma glucose ≥250 mg/dL) with glucose tablets and one with MDG. CONCLUSIONS: MDG may be more effective than insulin reduction for preventing exercise-induced hypoglycemia and may result in less postintervention hyperglycemia than ingestion of carbohydrate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Three mg of intranasal glucagon (1 mg glucagon per 10 mg dry powder) appears to have maximal effect.1231–1235”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1234]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physical activity/exercise and diabetes: A position statement of the American Diabetes Association
Colberg, S. R., Sigal, R. J., Yardley, J. E., Riddell, M. C., Dunstan, D. W., Dempsey, P. C., Horton, E. S., Castorino, K., & Tate, D. F. (2016) · Diabetes Care · doi:10.2337/dc16-1728 · Cited by 2,991 · cited 1×
“Accordingly, current guidelines recommend that all adults with type 1 diabetes engage in 150 min or more of moderate-to-vigorous intensity physical activity spread out over at least 3 days weekly (2).”
BackgroundSelf-citationExercise management in type 1 diabetes: a consensus statement
Riddell, M. C., Gallen, I. W., Smart, C. E., Taplin, C. E., Adolfsson, P., Lumb, A. N., Kowalski, A., Rabasa-Lhoret, R., McCrimmon, R. J., Hume, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30014-1 · Cited by 903 · cited 2×
“0 g of carbohydrate per minute of aerobic exercise depending on the timing of the exercise relative to the last insulin administration (23).”
BackgroundSelf-citationBarriers to Physical Activity Among Patients With Type 1 Diabetes
Brazeau, A.-S., Rabasa-Lhoret, R., Strychar, I., & Mircescu, H. (2008) · Diabetes Care · doi:10.2337/dc08-0720 · Cited by 595
The T1D exchange clinic registry
Beck, R. W., Tamborlane, W. V., Bergenstal, R. M., Miller, K. M., DuBose, S. N., Hall, C. A., & for the T1D Exchange Clinic Network (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1561 · Cited by 456
Self-citationAgiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Bohn, B., Herbst, A., Pfeifer, M., Krakow, D., Zimny, S., Kopp, F., Melmer, A., Steinacker, J. M., & Holl, R. W. (2015) · Diabetes Care · doi:10.2337/dc15-0030 · Cited by 321 · cited 2×
“the majority of patients with type 1 diabetesare sedentary, exercising less than 30 min a day, and most now meet the criteria forbeingoverweightorobese (1).”
Backgroundthe Diabetes Research in Children Network (DirecNet) Study Group (2006) · Diabetes Care · doi:10.2337/dc06-0495 · Cited by 217
Self-citationLascar, N., Kennedy, A., Hancock, B., Jenkins, D., Andrews, R. C., Greenfield, S., & Narendran, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108019 · Cited by 183
Galassetti, P., Tate, D., Neill, R. A., Morrey, S., Wasserman, D. H., & Davis, S. N. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1761 · Cited by 147
Gomez, A. M., Gomez, C., Aschner, P., Veloza, A., Muñoz, O., Rubio, C., & Vallejo, S. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814566233 · Cited by 139
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Exercise in adults with type 1 diabetes mellitus
Riddell, M. C., & Peters, A. L. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00756-6 · Cited by 144
Self-citationThe competitive athlete with type 1 diabetes
Riddell, M. C., Scott, S. N., Fournier, P. A., Colberg, S. R., Gallen, I. W., Moser, O., Stettler, C., Yardley, J. E., Zaharieva, D. P., Adolfsson, P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05183-8 · Cited by 101
Self-citationRickels, M. R. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14214 · Cited by 71
Self-citationExercise‐induced hypoglycaemia in type 1 diabetes
Cockcroft, E., Narendran, P., & Andrews, R. C. (2019) · Experimental Physiology · doi:10.1113/ep088219 · Cited by 80
“reduces the risk of hypoglycaemia without increased glucose postexercise (Rickels et al., 2018) Avoidance of alcohol • Alcohol should be avoided on days when exercise is done because it increases the risk of hypoglycaemia (Richardson et al.”
BackgroundInfluentialStable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue
Wilson, L. M., & Castle, J. R. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818757795 · Cited by 63
“Mini-dose glucagon also shows promise in preventing exercise-induced hypoglycemia in adults.(37) The main adverse events reported with mini-dose glucagon are nausea and vomiting which are rare and dose dependent.”
BackgroundInfante, M., Baidal, D. A., Rickels, M. R., Fabbri, A., Skyler, J. S., Alejandro, R., & Ricordi, C. (2021) · Artificial Organs · doi:10.1111/aor.14023 · Cited by 66
Self-citationWilson, L. M., Jacobs, P. G., Ramsey, K., Resalat, N., Reddy, R. K. K., Branigan, D. L., LEITSCHUH, J. A., Gabo, V. B., Guillot, F. H., Senf, B., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2267 · Cited by 64
Paldus, B., Morrison, D., Zaharieva, D. P., Lee, M. H., Jones, H., Obeyesekere, V. R., Lu, J., Vogrin, S., Gerche, A. L., McAuley, S. A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1593 · Cited by 56
Self-citationNovel preparations of glucagon for the prevention and treatment of hypoglycemia
Hawkes, C. P., De Leon, D. D., & Rickels, M. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1216-4 · Cited by 46
Self-citationAiello, E. M., Deshpande, S., Özaslan, B., Wolkowicz, K. L., Dassau, E., Pinsker, J. E., & Doyle, F. J. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100312 · Cited by 49
Mulla, C. M., Zavitsanou, S., Laguna Sanz, A. J., Pober, D., Richardson, L., Walcott, P., Arora, I., Newswanger, B., Cummins, M. J., Prestrelski, S. J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz197 · Cited by 43
Self-citationGlucagon-based therapy: Past, present and future
Patil, M., Deshmukh, N., Patel, M. V., & Sangle, G. V. (2020) · Peptides · doi:10.1016/j.peptides.2020.170296 · Cited by 37
Farias, A. P. D. C., & THORNTON, P. S. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00334-w · Cited by 38
New uses and formulations of glucagon for hypoglycaemia
Beato-Víbora, P. I., & Arroyo-Díez, F. J. (2019) · Drugs in Context · doi:10.7573/dic.212599 · Cited by 40
Hövelmann, U., Olsen, M. B., Mouritzen, U., Lamers, D., Kronshage, B., & Heise, T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13562 · Cited by 28
Glucagon and Its Receptors in the Mammalian Heart
Neumann, J., Hofmann, B., Dhein, S., & Gergs, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612829 · Cited by 32
Moser, O., Eckstein, M. L., Mueller, A., Birnbaumer, P., Aberer, F., Koehler, G., Sourij, C., Kojzar, H., Pferschy, P. N., Dietz, P., et al. (2019) · Nutrients · doi:10.3390/nu11061287 · Cited by 30
“A less commonly applied, but highly effective approach to reduce the risk of exercise-induced hypoglycemia faces subcutaneous mini-dose injections of glucagon [9]; in this study Rickels and colleagues showed that 150 mg of glucagon may be more effective than a 50% basal insulin reduction for preventing exercise-induce…”
BackgroundSteineck, I. I. K., Ranjan, A. G., Schmidt, S., Clausen, T. R., Holst, J. J., & Nørgaard, K. (2019) · Diabetologia · doi:10.1007/s00125-018-4807-8 · Cited by 27
Scott, S. N., Shepherd, S. O., Strauss, J. A., Wagenmakers, A. J. M., & Cocks, M. (2019) · Experimental Physiology · doi:10.1113/ep088097 · Cited by 27
Molveau, J., RABASA-LHORET, R. P. R., Taleb, N., Heyman, E., Myette‐Côté, É., Suppère, C., Berthoin, S., & Tagougui, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.01.003 · Cited by 27
Role of Glucagon in Automated Insulin Delivery
Wilson, L. M., Jacobs, P. G., & Castle, J. R. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.008 · Cited by 25
“Diabetes Obes Metab 2016;18(11):1110–9.”
Franc, S., Benhamou, P., Borot, S., Chaillous, L., Delemer, B., Doron, M., Guerci, B., Hanaire, H. P., Huneker, E., Jeandidier, N., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14442 · Cited by 24
Glucagon Therapy: A Comparison of Current and Novel Treatments
Sherman, J. J., & Lariccia, J. L. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0076 · Cited by 21
Diabetes Technology and Exercise
Riddell, M. C., Pooni, R., Fontana, F. Y., & Scott, S. N. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.011 · Cited by 19
Self-citationThe Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
Guo, K., Tian, Q., Yang, L., & Zhou, Z. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s343514 · Cited by 20
“92 Besides, patients with T1DM displayed absolute glucagon concentrations and a decrease in glucagon levels across the night comparable to those observed in the healthy control subjects.”
Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies
Demirbilek, H., Vurallı, D., Haris, B., & Hussain, K. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313837 · Cited by 23
“In addition, mini-doses of glucagon are now used for the management of hypoglycaemia following repeated, prolonged fasting in T1DM during Ramadan, as well as preventing exercise-induced hypoglycaemia.(81,82)”
MethodHyperglycemia But Not Hyperinsulinemia Is Favorable for Exercise in Type 1 Diabetes: A Pilot Study
ROMERES, D., Olson, K. J., Carter, R. E., Cobelli, C., Man, C. D., Basu, A., & Basu, R. (2020) · Diabetes Care · doi:10.2337/dc20-0611 · Cited by 19
Beck, R. W., Miller, K. M., & Foster, N. C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0129 · Cited by 15
Self-citationAronson, R., Riddell, M. C., Conoscenti, V., & JUNAIDI, M. K. (2023) · Diabetes Care · doi:10.2337/dc22-1145 · Cited by 15
Self-citation(Hybrid) Closed-Loop Systems: From Announced to Unannounced Exercise
Zimmer, R. T., Auth, A., Schierbauer, J., Haupt, S., Wachsmuth, N. B., Zimmermann, P., Voit, T., Battelino, T., Sourij, H., & Moser, O. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0293 · Cited by 18
Tagougui, S., Legault, L., Heyman, E., Messier, V., Suppère, C., Potter, K. J., Pigny, P., Berthoin, S., Taleb, N., & RABASA-LHORET, R. P. R. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0375 · Cited by 15
“29 Muscle vasodilatation.”
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems
Jacobs, P. G., Levy, C. J., Brown, S. A., Riddell, M. C., Çınar, A., Boughton, C. K., Breton, M. D., Dassau, E., Forlenza, G. P., Henderson, R. J., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251338754 · Cited by 24
Self-citationGlucagon for hypoglycaemia treatment in type 1 diabetes
Ranjan, A. G., Schmidt, S., & Nørgaard, K. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3409 · Cited by 17
“that a 150 μg glucagon injection before exercise was more effective than insulin dose reduction 5 min before exercise in preventing exercise‐induced hypoglycaemia and may result in less post‐intervention hyperglycaemia than with carbohydrate consumption.(42) For reduction of insulin to be successful in preventing hypo…”
BackgroundKovatchev, B. P., & Lobo, B. J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0117 · Cited by 10
Riddell, M. C., Shakeri, D., & Scott, S. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0427 · Cited by 11
“…Supplemental carbohydrate can be taken with AID systems with exercise when the activity is un-planned, 90 but we feel that the addition of solubilized glucagon just before or during the exercise, via dual hormone pump 91,92 or as a stand-alone injection, 93 would be another major advancement.”
Self-citationMolveau, J., RABASA-LHORET, R. P. R., Myette‐Côté, É., Messier, V., Suppère, C., Potter, K. J., Heyman, E., & Tagougui, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.953879 · Cited by 11
New Developments in Glucagon Treatment for Hypoglycemia
Hayward, L., & Wilson, L. M. (2022) · Drugs · doi:10.1007/s40265-022-01754-8 · Cited by 11
“Another study (NCT02882737) in 14 adults with type 1 diabetes compared the glucose changes with 45 min of cycling exercise where 200 mcg glucagon was administered either before or after exercise compared to glucagon given after 45 min of rest [129].”
BackgroundMcCarthy, O. M., Schmidt, S., Christensen, M. B., Bain, S. C., Nørgaard, K., & Bracken, R. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.981723 · Cited by 11
Lin, Y. K., Agni, A., Chuisano, S. A., Fetters, M. D., Funnell, M. M., Pop‐Busui, R., & DeJonckheere, M. J. (2023) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106231168859 · Cited by 10
Algeffari, M., Hussain, S., AlMogbel, T. A., Alsharidah, M. S., Alghadouni, H. A., & Mahmood, F. M. (2022) · Diabetes Care · doi:10.2337/dc21-1655 · Cited by 10
Diabetes Technology Meeting 2021
Xu, N. Y., Nguyen, K. T., DuBord, A. Y., Pickup, J. C., Sherr, J. L., Teymourian, H., Cengiz, E., Ginsberg, B. H., Cobelli, C., Ahn, D. T., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221090279 · Cited by 11
“118 Future directions can be glucagon solutions that will be utilized with insulin in bi-hormonal pumps or “glucose sensing glucagon” formulations which will be released in response to low glucose values in a similar concept as the glucose-responsive insulins.”
BackgroundKosinski, C., Herzig, D., Laesser, C. I., Nakas, C. T., Melmer, A., Vogt, A. P., Vogt, B., Laimer, M. W., Bally, L., & Stettler, C. (2020) · Diabetes Care · doi:10.2337/dc19-2250 · Cited by 14
The Glycemic Impact of Protein Ingestion in People With Type 1 Diabetes
Dao, G. M., Kowalski, G. M., Bruce, C. R., O'Neal, D. N., Smart, C. E., Zaharieva, D. P., Hennessy, D., Zhao, S., & Morrison, D. (2025) · Diabetes Care · doi:10.2337/dci24-0096 · Cited by 16
Woollam, M. D., Angarita-Rivera, P., Thakur, S., Daneshkhah, A., Siegel, A. P., Hardin, D. S., & Agarwal, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-00284-z · Cited by 9
Lundemose, S. B., McCarthy, O. M., Christensen, M. B., Laugesen, C., Bracken, R. M., Holst, J. J., Ranjan, A. G., & Nørgaard, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16103 · Cited by 8
Li, J., Jiang, X., & Wang, K. (2024) · Electronics · doi:10.3390/electronics13183727 · Cited by 6
Lundemose, S. B., Ranjan, A. G., Nørgaard, O., Suvitaival, T., & Nørgaard, K. (2025) · Diabetes Care · doi:10.2337/dc25-0702 · Cited by 6
Bishop, F. K., Addala, A., Corbin, K. D., Muntis, F. R., Pratley, R. E., Riddell, M. C., Mayer‐Davis, E. J., Maahs, D. M., & Zaharieva, D. P. (2023) · Nutrients · doi:10.3390/nu15112500 · Cited by 6
“Second, the use of technologies to facilitate improved glucose management during and after exercise, such as the use of Automated Insulin Delivery (AID) systems [88], glucagon therapy for exercise [89] and PA advisors [90] may help to reduce barriers to PA in individuals with T1D.”
BackgroundSelf-citationHypoglycemia in Type 1 Diabetes Mellitus
Şakar, K., & Çınar, N. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004108 · Cited by 9
External validation of a classifier of daily continuous glucose monitoring (CGM) profiles
Lobo, B. J., & Kovatchev, B. P. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105293 · Cited by 5
Mao, Y., Wen, S., Zhou, M., Zhu, S., & Zhou, L. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0153 · Cited by 7
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems
Jacobs, P. G., Levy, C. J., Brown, S. A., Riddell, M. C., Çınar, A., Boughton, C. K., Breton, M. D., Dassau, E., Forlenza, G. P., Henderson, R. J., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0129 · Cited by 7
Self-citationEmpfehlungen zur Diabetes-Behandlung mit automatischen Insulin-Dosierungssystemen
Berge, T. V. D., Biester, S., Biester, T., Buchmann, A.-K., Datz, N., Grosser, U., Kapitzke, K., Klusmeier, B., Remus, K., Reschke, F., et al. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1652-9011 · Cited by 5
New Medications for the Treatment of Diabetes
Garg, S. K., BRACKETT, S. J., Reinicke, T., & Hirsch, I. B. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.2512 · Cited by 6
Wang, Y., Bernatchez, F., Chouinard-Castonguay, S., Tremblay, M., Vanasse, A., Kinnard, N., Mégalli, M., Millette, M., Boulet, G., Henderson, M., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0290 · Cited by 5
“32 It is useful to prevent progression of hypoglycemia when oral intake is difficult (e.g., gastroenteritis) 33 and during exercise 34 —although we do not commonly recommend it in clinical practice.”
Tetzschner, R., Ranjan, A. G., Schmidt, S., & Nørgaard, K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00696-x · Cited by 4
Tinti, D., & Rabbone, I. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01443-1 · Cited by 4
Considerations in the Care of Athletes With Type 1 Diabetes Mellitus
Pujalte, G. G. A., Alhumaidi, H., Ligaray, K. P. L., Vomer, R. P., Israni, K., Abadin, A. A., & Meek, S. (2022) · Cureus · doi:10.7759/cureus.22447 · Cited by 9
Is Mini-Dose Glucagon the Answer to Preventing Exercise-Related Dysglycemia?
Castle, J. R. (2018) · Diabetes Care · doi:10.2337/dci18-0024 · Cited by 3
Kühne, T., Wallace, E., Herzig, D., Helleputte, S., Scott, S. N., Pickles, J., Melmer, A., & Stettler, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15580 · Cited by 2
“5 However, they may not be unrestrictedly applicable, as fructose may be too sweet for some individuals, high-intensity bouts cannot be integrated into all exercise modalities, and glucagon bears the risk of nausea and hyper-glycaemia.”
BackgroundAlgeffari, M., Hussain, S., Alsharidah, M. S., Alkhalifah, S., & AlMogbel, T. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093222 · Cited by 2
Yardley, J. E., & Colberg, S. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89843-0.00025-8 · Cited by 1
Rafi, E., Lewis, C. J., & Hatipoğlu, B. (2023) · JCEM Case Reports · doi:10.1210/jcemcr/luad171 · Cited by 2
“We chose 150 mcg and 300 mcg as starting doses based on improvements in exercise-induced hypoglycemia in patients with type 1 diabetes mellitus (9).”
MethodLundemose, S. B., Laugesen, C., Ranjan, A. G., & Nørgaard, K. (2025) · Diabetic Medicine · doi:10.1111/dme.15512 · Cited by 2
Dual-hormone Automated Insulin Delivery
Leelarathna, L., & Choudhary, P. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.370 · Cited by 1
Basal Insulin Adjustments and Continuous Glucose Monitoring During Exercise in Type 1 Diabetes
Zaharieva, D. P. (2018) · YorkSpace (York University)
Ketoazidose hinterlässt bleibende Schäden
Stiefelhagen, P. (2019) · CME · doi:10.1007/s11298-019-7160-4
Scott, S. N., Riddell, M. C., & Yardley, J. E. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-030-33376-8_25
Self-citationLe glucagon nasal, une innovation bien sentie
Benhamou, P. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.07.005
Glucagon in treatment of hypoglycemia - novelties
Brož, J., Malinovská, J., Brunerová, L., & Urbanová, J. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.022 · Cited by 1
Advances in Exercise and Nutrition as Therapy in Diabetes
Zaharieva, D. P., & Riddell, M. C. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.2508 · Cited by 1
Self-citationBerge, T. V. D., Biester, S., Biester, T., Buchmann, A.-K., Datz, N., Grosser, U., Kapitzke, K., Klusmeier, B., Remus, K., Reschke, F., et al. (2022) · Diabetes aktuell · doi:10.1055/a-1851-2883
Solà, C., Lundemose, S. B., McCarthy, O. M., & Nørgaard, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70085
“9 Similarly, in our original study, 4 the use of low-dose glucagon in individuals with T1D using an AID system was associated with higher mean plasma glucose values at the end of the exercise, but in the present sub-analysis, no differences were observed in any glycaemic parameters during the…”
Can Mini-Dose Glucagon Prevent Fasting-Induced Hypoglycemia and Preserve Fasting?
Algeffari, M. (2025) · Cureus · doi:10.7759/cureus.98620 · Cited by 1
“In this context, researchers have conducted multiple studies demonstrating that MDG is a practical and effective approach for managing impending hypoglycemia in individuals with T1D, particularly during periods of poor oral intake or during exercise [36,38].”
Molveau, J. (2025) · theses.fr (ABES) · doi:10.70675/bd2bda54z3647z4fc4z9eebz1d71ad50a8b2
Kinetics of Hypoglycemia in Diabetes Patients Informs Development of New Modes of Glucagon TherapyPreprint
Li, J., Byrne, C., Liang, J., Lee, S., Lyhne, M. K., Meng, A., Ling, S. R., Li, S., Lopes, A., Khosravi, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.05.729994
“Glucagon mini-dosing has been proposed as an effective treatment for several hypoglycemic conditions including in children with impending or mild hypoglycemia 10 , and prevention of exercise-related hypoglycemia 11 .”
INSIGHT: Ingest and Standardize Glucose Harmonization Tool
Ehlert, B., -, K. S., Katarya, D., Wu, Y., Wang, T., & Snyder, M. P. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261467778
Roadmap to Fully Closing the Loop to Optimize Health in Type 1 Diabetes
Marks, B. E., Hilliard, M. E., Kovatchev, B. P., Moser, O., Tanenbaum, M. L., Ackeifi, C. A., Ahn, D. T., Ajjan, R., Albanese-O’Neill, A., BAKHSH, A. M. K., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261496643
Self-citation
Metadata
- Authors
- Rickels, M. R., DuBose, S. N., Toschi, E., Beck, R. W., Verdejo, A. S., Wolpert, H., Cummins, M. J., Newswanger, B., Riddell, M. C., T1D Exchange Mini-Dose Glucagon Exercise Study Group, Rickels, M., Peleckis, A., Evangelisti, M., Dalton-Bakes, C., Fuller, C., Toschi, E., Wolpsert, H., Middelbeek, R., Cherng Jye, L. S., Shahar, J., Slyne, C., Edwards, S., Castillo, A. A., DuBose, S. N., Beck, R. W., Verdejo, A. S., Cummins, M., Newswanger, B., & Prestrelski, S.
- Affiliations
- Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
- Joslin Diabetes Center (US)
- Xeris Pharmaceuticals, Inc., Austin, TX
- York University (CA)
- Corresponding author
- T1D Exchange Mini-Dose Glucagon Exercise Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-05-18
- Volume
- 41
- Issue
- 9
- Pages
- 1909-1916
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6463733
- OpenAlex
- W2803450541
- Cited by
- 79
- References
- 25
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 4 · 2023: 9 · 2022: 14 · 2021: 9 · 2020: 10 · 2019: 16 · 2018: 4
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leona M. and Harry B. Helmsley Charitable Trust
- U.S. Public Health Service (UL1-TR-001878, P30-DK-19525)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, exercise-induced hypoglycemia, glucagon, insulin pump therapy, hyperglycemia
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Fasting, Female, Glucagon, Glucose, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Male, Exercise, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.